Publications
59
Citations
1,565
Est. group size
—
Recurring co-author estimate
Active years
20
Publishing since 2007
Matthew Ohr's work focuses on eye diseases affecting the retina and macula, including conditions like diabetic macular edema, retinal vein occlusion, and age-related macular degeneration. His research spans clinical trials of injectable drug treatments (anti-VEGF therapies), advanced retinal imaging techniques (optical coherence tomography), and drug delivery methods for treating eye conditions. This work would suit students interested in translational ophthalmology research that bridges clinical trials, imaging technology, and drug distribution modeling.
Publication output peaked around 2019 and has generally declined since, settling into a slower but steady pace of a few papers per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- In vivo imaging of the outer retina after an autologous neurosensory retinal free flap transplantation for a refractory macular hole closure
Journal of Medical Case Reports · 2026
- Computer Modeling of Bevacizumab Drug Distribution After Intravitreal Injection in Rabbit and Human Eyes
2026
- Murine Biocompatibility Evaluation of an Albumin‐Derived Complex and Nanoparticle Delivery System for Ocular Applications
Journal of Biomedical Materials Research Part A · 2026
- Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study
British journal of surgery · 2025
- Best Practices for High-Quality Anterior Segment Optical Coherence Tomography Imaging of Eyes with the Port Delivery Platform Implant
Diagnostics · 2025
- TENAYA and LUCERNE
Ophthalmology · 2024
- Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes
Journal of Pharmaceutical Sciences · 2024
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
The Lancet · 2023
- Faricimab Treat-and-Extend for Diabetic Macular Edema
Ophthalmology · 2023
- Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial
Japanese Journal of Ophthalmology · 2023
- Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial
JAMA Ophthalmology · 2023
- HIGH-RESOLUTION IMAGING OF THE OUTER RETINA IN TYPE 2 ACUTE MACULAR NEURORETINOPATHY
Retinal Cases & Brief Reports · 2023
- Computer Modeling of Bevacizumab Drug Distribution After Intravitreal Injection in Rabbit and Human Eyes
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion
JAMA Ophthalmology · 2022
- Foveal Phase Retardation Correlates With Optically Measured Henle Fiber Layer Thickness
Frontiers in Medicine · 2022
- Investigative Ophthalmology & Visual Science×13
- JAMA Ophthalmology×3
- Ophthalmology×2
- Graefe s Archive for Clinical and Experimental Ophthalmology×2
- Ophthalmic surgery, lasers & imaging retina×2
- Duriye Damla Sevgi
Medicine · Indiana University
- Michael Larsen
Medicine · Indiana University
- Amogh Iyer
Medicine · The Ohio State University
- Ali Torkashvand
Medicine · Indiana University
- Sudha K. Iyengar
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile